Although the BRAFV600E mutation could not be a such specific diagnostic marker in the genetic panel of brain tumors as GG, the differential diagnosis of GG can be established with the combination of its histological features with CD34 immunoreactive, BRAFV600E mutation and IDH1/2 wild type (Blümcke et al., 2016; Slegers and Blumcke, 2020). Here, CD34 is linked to brain neoplasm.